SC
AVBP icon

Steven Cohen’s ArriVent BioPharma AVBP Stock Holding History

Steven Cohen’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.7M Sell
566,796
-181,399
-24% -$5.35M 0.02% 903
2026
Q1 		$17.3M Buy
748,195
+531,535
+245% +$12M 0.02% 885
2025
Q4 		$4.36M Buy
+216,660
New +$4.51M ﹤0.01% 1939
2024
Q2 		– Sell
-28,900
Closed -$516K – 2543
2024
Q1 		$516K Buy
+28,900
New +$583K ﹤0.01% 1641

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Steven Cohen's AVBP Position: Q2 2026 in Review

Steven Cohen reduced its ArriVent BioPharma (AVBP) stake by 24% in Q2 2026, selling an estimated $5.35M and leaving 566,796 shares worth $19.7M. The position accounts for 0.02% of the portfolio, ranked #903.

Steven Cohen first reported a position in AVBP in Q1 2024 and has held it in 4 quarters since. 156 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Steven Cohen held 566,796 shares of ArriVent BioPharma worth $19.7M as of Q2 2026.
  • Steven Cohen sold 181,399 ArriVent BioPharma shares in Q2 2026, an estimated $5.35M.
  • ArriVent BioPharma made up 0.02% of Steven Cohen's portfolio in Q2 2026, its #903 holding.
  • Steven Cohen first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 4 quarters since.
  • 156 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.